Intuitive Surgical, Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Intuitive Surgical, Inc. stock analysis ISRG overview
Slightly Bullish +25

Got $1,000? Which of These Beaten-Down Healthcare Stocks Is Worth Buying?

📉 Intuitive Surgical and Vertex Pharmaceuticals have both significantly underperformed the broader market this year despite their strong long-term track records.

⚠️ Intuitive Surgical faces multiple headwinds including steep tariffs on medical devices and increased competition in the robotic-assisted surgery market from Medtronic and Johnson & Johnson.

💰 Valuation concerns are present for Intuitive Surgical, which trades at a forward earnings multiple of 44.3x compared to a healthcare sector average of 16.5x.

📈 Despite challenges, Intuitive Surgical continues to post strong financial results with expanding gross margins and growth driven by its fifth-generation da Vinci system.

🛡️ The company possesses a wide economic moat due to high switching costs and operates in an underpenetrated niche within robotic-assisted surgery.

📉 Vertex Pharmaceuticals shares have dropped 14% over the past year as its core cystic fibrosis business matures while new product launches have faced setbacks.

💊 Vertex's core cystic fibrosis drugs are expected to generate dependable revenue until at least the mid-2030s when patent exclusivity expires.

🌍 Vertex is expanding into new geographic regions and developing therapies for patients currently ineligible for its existing treatments.

🔬 Pipeline highlights include povetacicept for IgA nephropathy, which showed strong phase 3 results earlier this year, and inaxaplin for kidney disease expected to approve within three years.

💼 Vertex shares are trading around $425 each, allowing an investor with $1,000 to purchase a pair of shares for long-term holding.

⚖️ The article suggests Intuitive Surgical may be attractive for long-term investors looking to hold shares for a decade or more despite current valuation issues.

🧠 Vertex is viewed as a great stock to buy on the dip due to its diversified pipeline prospects and mature but profitable cystic fibrosis franchise.

🛒 With $1,000 invested in either company today, an investor can acquire two shares of Intuitive Surgical trading at approximately $460 per share.

🚀 The Motley Fool notes that while both healthcare giants offer opportunities, their recent performance has lagged behind their historical 10-year returns.

⚠️ Investors are reminded that Intuitive Surgical was not included in the Motley Fool Stock Advisor's current top 10 picks for immediate buying recommendations.

Bullish Signals
  • Intuitive Surgical has continued to post strong financial results in the first quarter, with revenue and earnings growing at a good clip.
  • Gross margins expanded for Intuitive Surgical in the first quarter, while its installed base grew largely thanks to the fifth generation of its da Vinci system.
  • Intuitive Surgical possesses a vast addressable market in the underpenetrated robotic-assisted surgery niche and maintains a wide moat from high switching costs.
  • The company can likely fend off tariff threats through price raises, demonstrating pricing power despite headwinds.
  • For long-term investors holding shares for a decade or more, Intuitive Surgical remains attractive at approximately $460 per share.
  • Vertex Pharmaceuticals' core cystic fibrosis business should continue generating dependable revenue until at least the mid-2030s before patent exclusivity expires.
  • Vertex is expanding into new regions to increase its addressable market and developing therapies to target CF patients ineligible for current treatments.
  • Vertex recently posted strong phase 3 results for povetacicept, an investigational medicine for IgA nephropathy that seems destined for approval.
  • The company's pipeline includes other promising candidates like inaxaplin for kidney disease that could earn approval within the next three years.
  • Vertex's current non-CF products, including Journavx for acute pain, should eventually contribute meaningfully to revenue growth.
Risk Factors
  • Intuitive Surgical has already significantly underperformed the broader market this year, indicating potential ongoing struggles.
  • Steep tariffs are affecting Intuitive Surgical's financial results, and any increase or lack of relief could compound negative effects on earnings over time.
  • Increased competition in the robotic-assisted surgery market is emerging, with Medtronic launching the Hugo system for urologic procedures while Johnson & Johnson plans to enter the space.
  • Intuitive Surgical is trading at 44.3x forward earnings compared to the healthcare sector's 16.5x average, meaning the stock is priced for perfection despite current headwinds.
  • Vertex Pharmaceuticals faces a mature core business in cystic fibrosis that is no longer driving significant growth, having lost much of its expansion potential.
  • Efforts by Vertex Pharmaceuticals to diversify its portfolio have so far resulted in approved medicines generating little revenue, contributing to the stock's 14% decline over the past year.
  • Vertex Pharmaceuticals' key medicines will only continue generating dependable revenue until the mid-2030s before losing patent exclusivity.
  • Intuitive Surgical was not included in The Motley Fool Stock Advisor's top 10 list of recommended stocks for investors to buy now.
Full Analysis
The article evaluates Intuitive Surgical (NASDAQ: ISRG) and Vertex Pharmaceuticals (NASDAQ: VRTX) as beaten-down healthcare stocks that may offer opportunities for patient investors with approximately $1,000 to deploy. While both companies have delivered strong returns over the last decade, they have recently underperformed due to specific headwinds. Intuitive Surgical faces challenges related to steep tariffs on its medical devices, intensifying competition in the robotic-assisted surgery market from rivals like Medtronic's Hugo system and Johnson & Johnson, and a valuation of 44.3x forward earnings compared to a 16.5x average for the healthcare sector. Despite these concerns, the company continues to show robust financial performance, with growing revenue, expanding gross margins, and a larger installed base driven by its fifth-generation da Vinci system, which creates a wide moat through high switching costs. The analysis suggests that for long-term holders, Intuitive Surgical remains attractive despite being priced for perfection, allowing an investor $1,000 to purchase two shares at approximately $460 each. Vertex Pharmaceuticals is noted as having suffered a 14% decline over the past year due to its core cystic fibrosis (CF) business maturing and struggles diversifying its portfolio with limited revenue from new launches. However, the company retains strong prospects through the mid-2030s as it maintains patent exclusivity for essential CF medications that patients require indefinitely. Vertex is expanding into new geographic regions and developing therapies for previously ineligible CF patients. Additionally, recent phase 3 results for povetacicept, an investigational medicine for IgA nephropathy (kidney disease), suggest potential approval and future growth, while other late-stage pipeline candidates like inaxaplin for APOL-1 mediated kidney disease could gain approval within three years. Existing non-CF products such as Journavx are also expected to contribute meaningfully to revenue, making the stock an attractive buy on the dip at roughly $425 per share, which would allow for two shares with a $1,000 investment. The article concludes by recommending against buying Intuitive Surgical right now in favor of other stocks identified by The Motley Fool Stock Advisor analyst team. While Intuitive Surgical is not part of the current top 10 list, the text cites historical examples to illustrate the potential outperformance of Stock Advisor's selections, noting that a $1,000 investment in Netflix on December 17, 2004, would have grown to $504,832 by now, and an investment in Nvidia on April 15, 2005, would have reached $1,223,471. The Stock Advisor's total average return is highlighted at 971%, significantly outperforming the S&P 500's 202% return, suggesting that investors seeking monster returns should consider the latest top 10 list instead of allocating capital to Intuitive Surgical at this time.